Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
Author:
Affiliation:
1. Department of Clinical Research in Breast Cancer, Cancer Hospital III/NCI, Rua Visconde de Santa Isabel no 274, Vila Isabel, Rio de Janeiro, Brazil
2. National Cancer Institute (INCA), Rio de Janeiro, Brazil
Abstract
Publisher
SAGE Publications
Subject
Oncology
Link
http://journals.sagepub.com/doi/pdf/10.1177/1758835919853971
Reference32 articles.
1. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
2. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
3. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
4. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
5. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12
2. Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer;Asian Journal of Surgery;2024-07
3. Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer;International Journal of Molecular Sciences;2022-12-08
4. Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy;Cancers;2021-12-17
5. Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens;Current Medicinal Chemistry;2021-04-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3